Alvotech Partners with Dr. Reddy’s for Keytruda Biosimilar Development

Alvotech ( (ALVO) ) has shared an announcement.

On June 5, 2025, Alvotech announced a collaboration with Dr. Reddy’s Laboratories to co-develop a biosimilar candidate to Keytruda, a major cancer treatment. This partnership aims to leverage both companies’ expertise in biosimilars to accelerate development and expand global reach, potentially increasing the availability of affordable cancer therapies worldwide.

The most recent analyst rating on (ALVO) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.

Spark’s Take on ALVO Stock

According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.

Alvotech’s strong earnings call and product pipeline are promising, but financial instability and high leverage pose significant risks. The technical analysis provides a moderately positive outlook, while the high P/E ratio indicates market optimism. Addressing financial challenges is crucial for sustained growth.

To see Spark’s full report on ALVO stock, click here.

More about Alvotech

Alvotech is a global biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide. The company aims to be a leader in the biosimilar space by delivering high-quality, cost-effective products and services. Alvotech has a diverse pipeline targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer, and has formed strategic commercial partnerships across the globe to enhance its market reach.

Average Trading Volume: 189,738

Technical Sentiment Signal: Hold

Current Market Cap: $3.13B

For an in-depth examination of ALVO stock, go to TipRanks’ Stock Analysis page.